SwedenBIO Insights: Who Will Pay? Building Market Need into the Biotech Value Journey

Good science alone does not create company value. Investors and partners ask three questions early. How large is the market for your chosen indication? What will it cost to get there? How far must the project go before it can be financed or partnered? Too often, willingness to pay and market validation are left until it's too late.​

At this breakfast seminar, a SwedenBIO Insight seminar organised by SwedenBIO's Business Strategy group, life science leaders take you through three key steps using real company cases:​

  • choosing the right indication​
  • understanding who will pay for your product​
  • having your product evaluated by people outside the company​

We'll share the decisions that increased the value of their companies, and the lessons learned along the way. Speakers include Jens Lindberg, CEO of Medivir, Jimmie Hofman, CBO of Vicore Pharma and Sofia Heigis, CEO of Oncopeptides.​

You'll leave with one or two concrete actions you can apply to your own development plan, and time to talk them over with peers afterwards.​

 

Date & time: Friday, November 20, 2026, 8:30 AM - 10:30 AM

Location: Bird & Bird, Norrlandsgatan 15, Stockholm or online

 

Program

8:30 AM - 9:00 AM

Registration and Coffee

 
9:00 AM - 9:05 AM

Welcome words by SwedenBIO and Bird&Bird​

 
9:05 AM - 9:10 AM

The value inflection journey

SwedenBIO Business Strategy Working Gorup
9:10 AM - 9:25 AM

Choosing your indication

Jens Lindberg, Medivir
9:25 AM - 9:40 AM

Who will pay? Analysing willingness to pay

Jimmie Hofman, Vicore Pharma
9:40 AM - 9:55 AM

External evaluation of your product

Sofia Heigis, Oncopeptides
9:55 AM - 10:00 AM

Q&A and closing​

Jens Lindberg, Medivir
Sofia Heigis, Oncopeptides
SwedenBIO Business Strategy Working Gorup
10:00 AM - 10:30 AM

Mingle

 

Organized by

Hosted at

Bird & Bird, Stockholm

 

        General terms & conditions      Privacy policy      Cookie policy      Data overview